GelMEDIX, Inc.
June 16, 2025
Company Presentation
Ophthalmology
GelMEDIX is a preclinical ophthalmology company, developing a retinal pigment epithelial (RPE) cell therapy to treat Geographic Atrophy, the leading cause of blindness in American adults. The first and recently approved treatments have marginal clinical benefit, and current retinal cell therapies in= clinical development have shown encouraging early benefits, but suffer from fundamental procedural limitations potentially limiting their utility. GelMEDIX's proprietary, in situ forming hydrogel technology provides an injectable scaffold that protects cells during injection and provides a framework for tissue regeneration while localizing them to the target site, overcoming the limitations of current approaches. GelMEDIX has demonstrated compelling pre-clinical evidence of overcoming the delivery challenges with potential to regenerate the retina in both porcine and rabbit models. GMP process development will be complete in the second half of 2025 with IND-enabling studies commencing.
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
Allogenic iPSC-derived RPE cell therapy with hydrogel formulation for treating Geographic Atrophy
CEO
Max Cotler
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
IND for lead program
What is your next catalyst (value inflection) update?
December 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}